With the development of the first GIP/GLP-1 co-agonist, tirzepatide, there has been an exponential increase in the effectiveness of incretin-mimetic pharmacological therapy for weight control in obese patients with and without diabetes
Such studies are at an early stage, and little is known of the response to differing regioisomers
So it's really interesting how this field is evolving because the omics, as you put it, whether it's proteomics, and now we're learning also about the epigenome and what brings us to the potential that this class of drugs would have an impact on health span in all people, not just those who are obese
Muscle dysfunction or weakness can occasionally last a lifetime
Moreover, beyond KRAS, key mutations in TP53, SMAD4, and CDKN2A cooperatively drive PDAC tumorigenesis, metabolic reprogramming, metastasis, and therapy resistance (Fig
Krishnan A, Abdullah TS, Mounajjed T et al (2017) A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition
